Early reduction in left ventricular contractile reserve detected by dobutamine stress echo predicts high-dose chemotherapy-induced cardiac toxicity

International Journal of Cardiology

Volumn 111, Issue 1, 2006, Pages 120-126

  Civelli, Maurizio ^a   Cardinale, Daniela ^a   Martinoni, Alessandro ^a   Lamantia, Giuseppina ^a   Colombo, Nicola ^a   Colombo, Alessandro ^a   Gandini, Sara ^a   Martinelli, Giovanni ^a   Fiorentini, Cesare ^a   Cipolla, Carlo M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Dobutamine; High dose chemotherapy; Left ventricular contractile reserve; Left ventricular dysfunction

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; EXERCISE TEST; FEMALE; HEART CONTRACTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTONIC AGENTS; DOBUTAMINE; ECHOCARDIOGRAPHY, STRESS; FEMALE; HEART DISEASES; HUMANS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33745691858     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.07.029     Document Type: Article

References (42)

1. The French Adjuvant Study Group. Benefit of high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-years follow-up results of French Adjuvant Study Group 05 Randomized trial. J Clin Oncol 19 (2001) 602-611
2. Basser R.L., Bik To L., Collins J.P., et al. Multicyle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up. J Clin Oncol 17 (1999) 82-92
3. Schrama J.G., Holtkamp M.J., Baars J.W., Schornagel J.H., and Rodenhuis S. Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer 88 (2003) 1831-1838
4. Gianni A.M., Siena S., Bregni M., et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes; five years results. J Clin Oncol 15 (1997) 2312-2321
5. Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., and Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324 (1991) 808-815
6. Boujon B., Lechat P., Mantz J., et al. Echocardiographic detection of adriamycin cardiotoxicity. Study of the relationship between the shortening fraction-constraint and the systolic shortening fraction-diameter of the left ventricle. Arch Mal Coeur 82 (1989) 167-175
7. Merchandise B., Schroeder E., Bosly A., et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118 (1989) 92-98
8. Pellikka P.A., Roger V.L., Oh J.K., Miller F.A., Seward J.B., and Tajik A.J. Stress echocardiography: Part II. Dobutamine stress echocardiography: techniques, implementation, clinical applications, and correlations. Mayo Clin Proc 70 (1995) 16-27
9. Picano E., and Trivieri M.G. Pharmacologic stress echocardiography in the assessment of coronary artery disease. Curr Opin Cardiol 14 (1999) 464-470
10. Afridi I., Kleiman N.S., Raizner A.E., and Zoghbi W.A. Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation 91 (1995) 663-670
11. Senior R., and Lahiri A. Role of dobutamine echocardiography in detection of myocardial viability for predicting outcome after revascularization in ischemic cardiomyopathy. J Am Soc Echocardiogr 14 (2001) 240-248
12. Naqvi T.Z., Goel R.K., Forrester J.S., and Siegel RJ. Myocardial contractile reserve on dobutamine echocardiography predicts late spontaneous improvement in cardiac function in patients with recent onset idiopathic dilated cardiomyopathy. J Am Coll Cardiol 34 (1999) 1537-1541
13. Ramahi T.M., Longo M.D., Cadariu A.R., et al. Dobutamine-induced augmentation of left ventricular ejection fraction predicts survival of heart failure patients with severe non-ischaemic cardiomyopathy. Eur Heart J 22 (2001) 849-856
14. Paraskevaidis I.A., Adamopoulos S., Tsiapras D., Karatzas D., and Kremastinos D.T. Prognostic usefulness of echocardiographic dobutamine in younger (14 to 25 years) and older (40 to 55 years) patients with idiopathic dilated cardiomyopathy. Am J Cardiol 93 (2004) 251-255
15. Klewer S.E., Goldberg S.J., Donnerstein R.L., Berg R.A., and Hutter J.J. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 19 (1992) 394-401
16. De Wolf D., Suys B., Maurus R., et al. Dobutamine stress echocardiography in the evaluation of late anthracyline cardiotoxicity in childhood cancer survivors. Pediatr Res 39 (1996) 504-512
17. De Wolf D., Suys B., Verhaaren H., Matthys D., and Taeymans Y. Low-dose dobutamine stress echocardiography in children and young adults. Am J Cardiol 81 (1998) 895-901
18. Elbl L., Hrstkova H., Chaloupka V., Novotny J., and Michalek J. The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography. Neoplasma 50 (2003) 191-197
19. Lanzarini L., Bossi G., Laudisa M.L., Klersy C., and Arico' M. Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am Heart J (2000) 315-323
20. Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109 (2004) 2749-2754
21. Bregni M., Siena S., Di Nicola M., et al. Comparative effects of granulocyte-macrophage colony-stimulating factor after high-dose cyclophosphamide. J Clin Oncol 14 (1996) 628-635
22. Rosenthal D.S., and Braunwald E. Cardiac effects of radiation therapy and chemotherapy. In: Brauwald E. (Ed). Heart disease: a textbook of cardiovascular medicine (2001), W.B. Saunders Company, Philadelphia, PA 1746-1751
23. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
24. Sahn D.J., DeMaria A., Kisslo J., and Weyman A. Recommendations regarding quantification in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
25. Hollander M., and Wolfe D.A. A distribution-free test for ordered alternatives base on friedman rank sum (Page). Non parametric statistical methods (1973), John Wiley and Sons, New York, NY 147-150
26. Hochberg Y., and Bejamini Y. More powerful procedures for multiple significance testing. Stat Med 9 (1990) 811-818
27. Seghatol F.F., Shah D.J., Diluzio S., et al. Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic or idiopathic dilated cardiomyopathy. Am J Cardiol 93 (2004) 854-859
28. Senior R., Kaul S., and Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll Cardiol 33 (1999) 1848-1854
29. Jourdain P., Funck F., Fulla Y., et al. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol. Eur J Heart Fail 4 (2002) 269-276
30. Basser R.L., Abraham R., Bik To L., Fox R.M., and Green M.D. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer. Ann Oncol 10 (1999) 53-58
31. Lipshultz S.E., and Colan S.D. The use of echocardiography and holter monitoring in the assessment of anthracycline-treated patients. In: Bricker J.T., Green D.M., and D'Angio G.J. (Eds). Long term complications of treatment of children and adolescents for cancer (1993), Wiley-Liss Inc, Philadelphia, PA 45-62
32. Swain S.M., Whaley F.S., and Ewer M.S. Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 97 (2003) 2869-2879
33. Pai V.B., and Nahata M.C. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Safety 22 (2000) 263-302
34. Schwartz R.G., McKenzie W.B., Alexander J., et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-years experience using serial radionuclide angiocardiography. Am J Med 82 (1987) 1109-1118
35. Marchandise B., Schroeder E., Bosly A., et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118 (1989) 92-98
36. Meinardi M.T., van Veldhuisen D.J., Gietema J.A., et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19 (2001) 2746-2753
37. Nagai H., Omi W., Yuasa T., et al. Ultrasonic analysis of anthracyclines-induced myocardial damage using cyclic variation of integrated bachscatter. J Am Soc Echocardiogr 16 (2003) 808-813
38. Speyer J.L., Green M.D., Kramer E., et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319 (1988) 745-752
39. Kolaric K., Bradamante V., Cervek J., et al. A phase II trial of cardioprotection with cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology 52 (1995) 251-255
40. Rodenhuis S., Bontenbal M., Beex L.V.A.M., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349 (2003) 7-16
41. Robison T.W., and Giri S.N. Effects of chronic administration of doxorubicin on myocardial β-adrenergic receptors. Life Sci 39 (1986) 731-736
42. 123I]Metaiodobenzylguanidine scintigraphy. Eur J Cancer 31 (1995) 23-31